Related Experiment Video

Updated: Aug 9, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma

Faustine X Luo1,2, Zhaohui Liao Arter1,2

  • 1University of California Irvine School of Medicine, Orange, CA, 92868, USA.

Lung Cancer (Auckland, N.Z.)
|November 6, 2024
PubMed

Insights

Adagrasib shows significant clinical benefits for advanced KRAS G12C-mutant non-small cell lung cancer, especially in managing brain metastases, offering a new treatment option.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • KRAS G12C-mutant non-small cell lung cancer (NSCLC) is a therapeutic challenge.
  • Targeting KRAS mutations directly has been historically difficult.

Purpose of the Study:

  • To evaluate the clinical efficacy of adagrasib in advanced KRAS G12C-mutant NSCLC.
  • To discuss adagrasib's advantages over other KRAS inhibitors.

Main Methods:

  • Review of clinical trial data, including KRYSTAL-1 Phase II and KRYSTAL-12 Phase III trials.
  • Analysis of progression-free survival (PFS) and objective response rate (ORR), including CNS response.

Main Results:

  • Adagrasib significantly improved median PFS compared to docetaxel in the KRYSTAL-12 trial.
  • Adagrasib demonstrated a 40% intracranial ORR in patients with CNS metastases.
  • While not reaching a 6-month PFS benchmark, adagrasib offers substantial clinical benefits.

Conclusions:

  • Adagrasib is an effective targeted therapy for KRAS G12C-mutant NSCLC.
  • Adagrasib provides significant clinical advantages, particularly for patients with central nervous system metastases.
  • Adagrasib represents a breakthrough in targeting the KRAS G12C mutation in NSCLC.
Keywords:
KRASG12C mutationsKRYSTALadagrasibintracranial efficacynon-small-cell lung cancersotorasibtargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...